[{"indications": "Indications\u00a0see notes above", "name": "PEGVISOMANT", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.5 Hypothalamic and pituitary hormones and anti-oestrogens", "6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens", "Anterior pituitary hormones", "Growth hormone receptor antagonists"], "cautions": "Cautions\u00a0liver disease (monitor liver enzymes\r\nevery 4\u20136 weeks for 6 months or if symptoms of hepatitis develop); diabetes mellitus (adjustment of antidiabetic therapy\r\nmay be necessary); possible increase in\r\nfemale fertility", "side-effects": "Side-effects\u00a0diarrhoea, constipation, nausea, vomiting, abdominal\r\ndistension, dyspepsia, flatulence, elevated liver enzymes; hypertension;\r\nheadache, asthenia, dizziness, drowsiness, tremor, sleep disturbances;\r\ninfluenza-like syndrome, weight gain, hyperglycaemia, hypoglycaemia;\r\narthralgia, myalgia; injection-site reactions (rotate injection sites\r\nto avoid lipohypertrophy), sweating, pruritus, rash; fatigue; hypercholesterolaemia;\r\nless commonly thrombocytopenia, leucopenia, leucocytosis, bleeding\r\ntendency", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128350.htm", "doses": ["By subcutaneous injection, initially 80\u00a0mg,\r\nthen 10\u00a0mg daily, increased in steps of 5\u00a0mg daily according to response;\r\nmax. 30\u00a0mg daily; child not recommended"], "pregnancy": "Pregnancy\u00a0avoid"}]